Pediatric MASLD: Beyond “Fatty Liver” Toward a Cardiometabolic Syndrome That Demands Early Action

A clinical and epidemiologic reading of the 2025 AASLD Practice Statement on MASLD evaluation and management in children

Leer este artículo en Español: masld en pediatria del higado graso

MASLD (Metabolic dysfunction–Associated Steatotic Liver Disease) is the term that has replaced the former NAFLD (Non-Alcoholic Fatty Liver Disease). It refers to steatotic liver disease associated with metabolic dysfunction—fat accumulation in the liver in individuals with metabolic abnormalities, in whom alcohol intake does not account for the hepatic injury.

Not all children with overweight or obesity develop MASLD, although the risk rises substantially. Obesity is the leading risk factor, but it is not synonymous with steatotic liver disease. Estimates suggest that up to 50–60% of children with severe obesity may develop MASLD.

To diagnose MASLD, the following are required: evidence of hepatic steatosis (by ultrasound, elastography, MRI, or histology) and at least one feature of metabolic dysfunction, such as overweight or obesity, type 2 diabetes, insulin resistance, dyslipidemia, hypertension, or metabolic syndrome. In pediatrics, MASLD is tightly linked to childhood obesity, hyperinsulinemia, and early disruption of the metabolic axis.

MASLD pathophysiology is complex and multifactorial. It is currently framed by the “multiple hits” hypothesis: insulin resistance, lipotoxicity, inflammation, and progression to MASH when steatosis is accompanied by inflammation and cellular injury. In that setting we speak of MASH (Metabolic dysfunction–Associated Steatohepatitis), the counterpart of the former NASH. Additional drivers include the gut–liver axis, genetic and epigenetic factors, and polymorphisms that shape both risk and progression.

There is no universal pharmacologic “cure.” Management is comprehensive and stepwise: lifestyle change (the foundation of therapy) as the central pillar, treatment of comorbidities, selective pharmacotherapy in certain cases, and advanced approaches when significant fibrosis or high-risk features are present.

The AASLD Practice Statement on the evaluation and management of metabolic dysfunction–associated steatotic liver disease (MASLD) in children (Hepatology; Epub April 29, 2025; print publication November 2025) is, above all, a normative document. It is not a randomized trial, not a cohort, and not a primary meta-analysis; it is an expert synthesis of the available evidence, organized into clinically actionable statements designed for real-world implementation. In PubMed it appears as an extensive work (Hepatology 2025;82(5):1352–1394) with a clearly pediatric focus. From an epidemiologic standpoint, documents of this type are judged by how clearly they define the public-health problem; how rigorously and transparently they grade the evidence; how sound their operational definitions are (who is included and excluded); how reasonable their screening and confirmatory pathways are; and, crucially, whether they can be implemented without net harm (overdiagnosis, stigma, costly testing cascades, or iatrogenesis).

The statement’s first epidemiologic strength is its premise of urgency: MASLD can no longer be treated as a niche subspecialty condition. In a high-level overview presented at DDW 2025, co-chair Jeffrey Schwimmer highlighted two figures that—while communicated in an accessible format—frame the scale of the problem and the cost of inaction: “about 10% of children” may have MASLD, and among those who reach pediatric gastroenterology and complete diagnostic evaluation, “~15% already have stage 3 fibrosis.” Epidemiologically, this is an explosive combination: a condition with meaningful population prevalence and a subgroup with advanced progression detected too late. The document therefore aligns with a classic secondary-prevention logic: if a detectable subclinical phase exists, and if the natural history can be modified through intervention—or at least through risk stratification and comorbidity control—then systematic screening may be justifiable.

A second, distinctly pediatric strength is conceptual: MASLD is not framed as “a liver disease,” but as a multisystem cardiometabolic condition requiring integration across primary care, nutrition, and mental health, and—when indicated—endocrinology, cardiology, and hepatology. Clinically this is accurate, and epidemiologically it is consistent with what we know about risk clustering: obesity, insulin resistance, dyslipidemia, hypertension, sleep disorders, and mental health conditions frequently co-occur. If the liver is treated in isolation, opportunities to reduce overall risk are missed. By design, the guidance aims to counter fragmented care: not simply “refer for elevated ALT” and disengage, but build coordinated care pathways.

Where the statement draws the most practical line—arguably its most debated yet most useful stance—is primary-care screening. Based on the DDW summary, the recommendation is to screen for MASLD in all children with overweight or obesity starting at age 10, unlike adult approaches that often restrict screening to those with additional high-risk factors. Epidemiologically, this accepts a trade-off: expanding to “all with excess weight” increases population sensitivity (more cases detected) at the cost of more false positives and greater follow-up burden. In pediatrics, the threshold for accepting that cost may be lower if late diagnosis carries substantial harm (advanced fibrosis, longer cardiometabolic risk trajectory) and if the initial test is inexpensive and accessible. In that context, the statement argues that adult screening algorithms perform poorly in children and that ALT remains the “best validated” screening tool in pediatrics, using pediatric-specific thresholds. This is a critical point: ALT is available, but imperfect as a population test; its positive predictive value depends strongly on prevalence in the subgroup tested (ALT screening in the general school population is not the same as ALT in children with obesity and/or comorbidities). In practice, the statement supports ALT as the entry point but emphasizes a complete workup when MASLD is suspected, aiming to contain diagnostic cascades and reduce attribution errors (“high ALT = fatty liver”) in settings where multiple etiologies of transaminase elevation exist.

The document also acknowledges two epidemiologic realities that, if ignored, create clinical bias. First: not every child with obesity develops MASLD; the DDW overview notes that only about “one in four” children with obesity may have MASLD. If care systems collapse into “obesity = MASLD,” overdiagnosis and stigma follow, and effort is diluted away from those truly at hepatic risk. Second: MASLD can occur with normal BMI; the summary suggests that roughly 30% of children with steatotic liver disease may have a normal BMI. Clinically, this forces us to assess the full phenotype—fat distribution, family history, ethnicity, insulin resistance, and dyslipidemia—rather than relying on BMI alone. Epidemiologically, it reminds us that BMI-only strategies will have blind spots and that “weight-centered prevention” does not capture the entire at-risk population.

For confirmatory diagnosis, the guidance—per the DDW summary—states that the best validated noninvasive technique to quantify steatosis in pediatrics is MRI–Proton Density Fat Fraction (MRI-PDFF), while acknowledging limited availability and offering alternative imaging approaches as well as scenarios in which biopsy should be considered to confirm diagnosis or stage severity. From an applied epidemiology perspective, this raises an equity dimension: if the “ideal” recommendation depends on non-universal technology, a two-tier system can emerge. The statement’s strength is that it does not remain trapped in the technological ideal and instead endorses pragmatism. The clinician’s challenge will be to avoid translating lack of MRI-PDFF into “do nothing,” or worse, into “do too much” (for example, premature biopsies without a solid indication) driven by uncertainty.

Therapeutically, the public summaries are deliberately sober: there are currently no medications approved specifically for pediatric MASLD/MASH, so the cornerstone remains intensive, family-centered lifestyle modification, ideally delivered by a multidisciplinary team. This conclusion is scientifically responsible, but it exposes an operational gap: in public health, “lifestyle change” fails when it is delivered as generic advice rather than as a structured, dosed intervention with follow-up. By emphasizing multidisciplinary care and including mental health, the statement appears to address that reality, because real-world success depends on adherence, family context, food insecurity, culture, sleep, stress, and access to safe spaces for physical activity. A key pediatric truth sits underneath this: children rarely control their environment; therefore, “treatment” is often treatment of the family system and the school and community context.

In terms of evidence quality, the statement also reflects a structural limitation in what has been publicly communicated: children have historically been excluded or underrepresented in trials of emerging therapies, prompting calls for dedicated pediatric trials and noninvasive biomarkers. Epidemiologically, this is a reminder not to extrapolate without rigor: what benefits adults with MASH may not translate directly to adolescents who are still growing, with different pubertal physiology, different exposure trajectories, and a different risk–benefit balance. It is a prudent message to prevent iatrogenesis driven by adult-centered therapeutic enthusiasm.

In sum, the AASLD Practice Statement serves a public-health function: it translates a prevalent and progressive condition into an action framework that can be executed from primary care and coordinated with subspecialties. Its strengths include framing MASLD as multisystem disease; endorsing early screening integrated into pediatric care; prioritizing ALT with pediatric thresholds while acknowledging the weakness of adult algorithms; and proposing a realistic diagnostic and therapeutic pathway without promising drugs that do not yet exist for children. Its tension points—where clinicians must be precise—include overdiagnosis risk if ALT is used automatically without context, the technology gap around MRI-PDFF, and the need to transform “lifestyle” into a structured, measurable intervention rather than moral advice.

From a comprehensive pediatric perspective, the closing message is clear: we cannot wait until these children “become adults” to finally recognize their disease. If a meaningful proportion are already reaching specialty care with advanced fibrosis, the window for secondary prevention is closing far too early.

Ismael Perdomo, MD

Pediatrician – Epidemiologist

Founder & CEO, With Ties of Love Inc.

Orlando, Florida, United States